VANCOUVER, May 22, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V:
SBM) (FSE: ZSB) ("Sirona") is pleased to announce it has
commissioned Contract Research Organization (CRO)
Roowin (www.roowin.com) to develop the final
chemical process required for large scale manufacturing of
TFC-1067. This is another important step in the commercialization
of Sirona's novel skin lightening agent.
Sirona anticipates the need for multiple kilogram production of
TFC-1067 in the short term and is therefore taking this necessary
intermediate step. Sirona will then proceed to manufacture an
inventory of TFC-1067 of up to 20 kilograms to be ready for
anticipated orders. Due to the high potency of the compound, each
kilogram will supply Sirona's active skin lightening ingredient to
produce ten thousand consumer size (fifty milliliters) containers
of finished product.
"The chemistry of TFChem (Sirona's subsidiary) is unique and our
science team has an excellent understanding of this chemistry. We
have already successfully worked on production of TFC-1067 at the
kilogram scale," reports Patrice Rool, CEO of Roowin. "Our
scientists will collaborate with TFChem to develop the most
efficient final process to manufacture TFC-1067. We are very
excited to be a part of the ongoing development of this innovative
skin lightener."
"Roowin's expertise in manufacturing process development will
move TFC-1067 closer to final commercialization. In addition, our
scientists at TFChem have developed new chemistry that will further
improve manufacturing efficiencies and lower cost of goods," Dr.
Verrico concluded. "The new manufacturing process for
TFC-1067 we anticipate will be used at manufacturing sites globally
down the road. Roowin has extensive experience with our chemistry
and we are excited to be working together again."
About Roowin
Roowin is a privately-owned Contract Research Organization (CRO)
headquartered in Riom (Auvergne), France. Its core business being in high
value-added fine chemistry, Roowin offers a large range of chemical
services. Roowin supports customers and partners to advance their
drug candidates from early research phase up to licensing out API
in phase II or to the Market for small batches, about 20
kilograms.
Roowin is accredited ISO 9001. Roowin's facilities include cGMP
facilities: Kilo-laboratory / Pilot plant. Roowin can accompany its
customers from early lead optimization through scale-up and
small-scale GMP synthesis up to medium scale GMP
manufacturing.
For more information, please visit www.roowin.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.